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The American Society for Bone and Mineral Research
appointed a 24 member multi-disciplinary task force, co-
chaired by Sundeep Khosla and Elizabeth Shane, to address
six key areas important for the definition, understanding and
study of bisphosphonate-related osteonecrosis of the jaw
(BRONJ). The task force addressed issues related to the
definition of BRONJ, epidemiology, risk factors, diagnostic
imaging, clinical management and areas for future research.
The Task Force Report will be published in the JBMR and
should be online by late summer.
Case definition
The Task Force separated the definition of confirmed and
suspected cases of BRONJ. A confirmed case was defined as an
area of exposed bone in the maxillofacial region that has not
healed within 8 weeks after identification by a health care
provider, in a patient who received bisphosphonate treatment
and was not exposed to radiation therapy in the craniofacial
region. A suspected case was defined as an area of exposed bone
in the maxillofacial region that has been present for less than 8
weeks, in a patient who received bisphosphonate treatment and
was not exposed to radiation therapy in the craniofacial region.
Epidemiology
The risk of BRONJ was estimated to be ~1 in <100,000
patient-treatment years regardless of causality. The inci-
dence in patients being treated for cancer is higher, probably
between 1-10%. Both dose and duration of bisphosphonate
(BP) use is related to risk, with the mean time to onset of 18
months with zoledronic acid, but 39-72 months for patients
treated with pamidronate. The odds ratio for i.v. BP use was
estimated at 4.24, using insurance claims data.
Diagnostic imaging techniques to characterize
and diagnose BRONJ 
Potentially useful imaging modalities were divided into
those that image bone structure (panoramic radiography,
computed tomography (CT), and cone beam computed
tomography (CBCT)); those that image marrow and soft tis-
sue (MRI); functional and physiological tests (scintigraphy
with technetium and positron emission tomography (PET));
and those that are currently experimental but may have
potential for development (optical coherence tomography
(OCT)). Another more novel approach is to use sequential
images to provide a temporal history of developing change.
Some of the imaging approaches may also be enhanced by
the contribution of contrast agents. While a number of imag-
ing approaches could be used to possibly diagnose BRONJ
at an early stage, considerable work needs to be done to
define the most appropriate technique(s). The Task Force
believes that the use of contrast agents combined with MRI,
and the manipulation of different planes of image may be
the most promising approach currently available for differ-
ential diagnosis. However, additional technological develop-
ment of some relatively new approaches, such as OCT or
CBCT, whose capabilities have not yet been fully explored,
may prove to be valuable for detecting early stage disease. 
Recommendations for clinical management
The Task Force made a number of recommendations for clin-
ical management, dividing them into general recommendations,
as well as recommendations for patients with (a) osteoporosis or
other non-malignant disease; (b) patients with malignancy; (c)
patients with established BRONJ. In general, for those with
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established BRONJ, surgical treatment should be conservative
or delayed. There are no data to suggest that stopping BP thera-
py will allow the ONJ to resolve, nor is there evidence that halt-
ing BP therapy prior to dental procedures is effective, because of
the long half-life of BPs in the skeleton. The best management
approach is still unclear and needs better definition.
Future research
On the clinical/epidemiological side, it will be important to
better define the true incidence of BRONJ, as well as to identi-
fy specific factors that put patients at risk. Because the risk of
BRONJ is affected by the dose and duration of BP treatment,
alternative dosing schedules could reduce the incidence of
BRONJ while maintaining the benefits of BP therapy. Another
area of future investigation should be to determine whether
there are salivary or crevicular fluid markers that could be used
as indicators of local bone metabolism. Outcome studies of
those patients with dental implants or who have had routine
dental therapy and also a history of current or past BP use
should be defined. A number of basic or animal studies could be
used to address these and other important questions. For exam-
ple, the cellular and molecular mechanisms by which BPs pre-
dispose to the development of BRONJ need to be studied, as
does the role of regional vascularization. Examination of the
bioavailability and distribution of the BPs in the skeleton, in rela-
tion to regional differences in bone metabolism and turnover,
will be important. The roles of oral infection, trauma and inflam-
matory/immune processes in the pathogenesis of BRONJ are
unclear. Development and validation of biomarkers for BRONJ
will also provide important diagnostic information.
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